Approved symbol MERTK
Approved name Tyrosine-protein kinase Mer
Alternative names Proto-oncogene c-Mer; Receptor tyrosine kinase MerTK
Protein family / class Receptor Tyrosine Kinase – TAM family (TYRO3, AXL, MERTK)
UniProt Q12866
Therapeutic area Oncology; Immunology
Design objective Type I, ATP-competitive; TAM-family aware design
Collection size 1105 molecules
Design method Machine learning; molecular docking
ADMET profiled Yes (predicted)
Status Available
Crystal structure ribbon diagram of MERTK tyrosine-protein kinase Mer kinase domain, Homo sapiens (PDB: 7AB0)

Why MERTK?

MERTK is a receptor tyrosine kinase that transduces extracellular signals into the cytoplasm upon ligand binding, regulating cell survival, migration, differentiation and phagocytosis of apoptotic cells.

It functions as an innate immune checkpoint in macrophages, a mechanism exploited by tumours to suppress anti-tumour responses. Kinase activation drives efferocytosis, clearing apoptotic cells without inflammation and limiting DAMP release. The process also upregulates PD-L1 on macrophages, dampening T cell activation and impairing antigen presentation.

No approved drugs yet, but multiple first-in-human trials support strong translational potential. Defined kinase activity and an accessible ATP-binding site make it well suited to small-molecule intervention.

Design approach

Designed against the MERTK kinase domain in a DFG-in conformation, targeting the ATP pocket with hinge engagement. Sequence and structural context of the TAM family (AXL, TYRO3) was considered during design; predicted selectivity ratios are not reported at this stage.

What the collection offers

  • Multi-objective design balancing predicted activity, ADMET, synthetic accessibility and novelty.
  • Scaffold diversity to support structure–activity exploration from the first round of testing.
  • Synthetic routes based on commercially available building blocks.
  • Filtered against common toxicity and assay-interference liabilities (predicted).
  • Available by molecular series, allowing focused follow-up rather than acquisition of the full set.

What we built

Tailored chemical collection for MERTK, optimized with multi-objective design (predicted activity, ADMET, synthesizability, novelty).

Availability

Collection available for collaboration or licensing (by molecular series or full set)

References

  • Myers KV, Amend SR, Pienta KJ (2019). Targeting Tyro3, Axl and MerTK (TAM receptors): implications for macrophages in the tumor microenvironment. Published in Molecular Cancer

Read the article : https://pubmed.ncbi.nlm.nih.gov/31088471/

  • Huelse JM, Fridlyand DM, Earp S, DeRyckere D, Graham DK (2020). MERTK in cancer therapy: Targeting the receptor tyrosine kinase in tumor cells and the immune system. Published in Pharmacology & Therapeutics.
    Read the article : https://pubmed.ncbi.nlm.nih.gov/32417270/
  • UniProt (Q12866 – MERTK). Protein entry with details on function, ligands, and biological pathways.
    View on Uniprot : https://www.uniprot.org/uniprotkb/Q12866/entry